-
公开(公告)号：US20180319881A1
公开(公告)日：2018-11-08
申请号：US15969952
申请日：2018-05-03
Applicant: Novartis AG
Inventor： Sarah Schmidt Grant , Shamsah Kazani , Edward Khokhlovich , Jason Laramie , Robert Martin Strieter , Tricia Ann Thornton-Wells
Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating asthma, such as severe asthma, by employing IL-17 antagonists to a patient population defined by serum concentration of IgE and optionally also an eosinophil count in peripheral blood.
-
公开(公告)号：US20200277378A1
公开(公告)日：2020-09-03
申请号：US16764102
申请日：2018-11-16
Applicant: Novartis AG
Inventor： Catherine Anne Sabatos-Peyton , Jennifer Marie Mataraza , Kenzie MacIsaac , Eunice Kwak , Jason Faris , Glenn Dranoff , Marion Wiesmann , Fiona Sharp , Adam Crystal , John Scott Cameron , Robert Martin Strieter , Lilli Petruzzelli , Shamsah Kazani , David Andrew Sandham , Neil John Press , Keith Hoffmaster
Abstract: Combination therapies comprising PD-1 inhibitors and other therapeutic agents used to treat or prevent cancerous conditions and disorders as follow. Combination therapies of three agents which are a PD-1 inhibitor, a CXCR2 inhibitor and a CSF-1/1R binding agent for treating a pancreatic cancer or a colorectal cancer. Combination therapies of three agents which are a PD-1 inhibitor, a CXCR2 inhibitor and an inhibitor of either TIM-3, C-MET or A2aR for treating a pancreatic cancer or a colorectal cancer. Combination therapies of three agents which are a PD-1 inhibitor, a LAG-3 inhibitor and (i) an inhibitor of either TGF-beta, TIM-3, C-MET, IL-1b or MEK or (ii) a GITR agonist or (iii) an A2aR antagonist or (iv) a CSF-1/1R binding agent for treating a breast cancer. Combination therapies of two agents which are a PD-1 inhibitor and a CXCR2 inhibitor for treating a pancreatic cancer, a colorectal cancer, a lung cancer or a breast cancer.
-
公开(公告)号：US10676522B2
公开(公告)日：2020-06-09
申请号：US15969952
申请日：2018-05-03
Applicant: Novartis AG
Inventor： Sarah Schmidt Grant , Shamsah Kazani , Edward Khokhlovich , Jason Laramie , Robert Martin Strieter , Tricia Ann Thornton-Wells
Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating asthma, such as severe asthma, by employing IL-17 antagonists to a patient population defined by serum concentration of IgE and optionally also an eosinophil count in peripheral blood.
-
-
Search Results
3
records
(took 0.009 seconds)
